Kezar Life Sciences (NASDAQ:KZR) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Kezar Life Sciences (NASDAQ:KZR) announced its earnings results on Tuesday. The company reported ($2.77) earnings per share for the quarter, missing the consensus estimate of ($2.71) by ($0.06), Zacks reports.

Kezar Life Sciences Stock Down 8.4 %

KZR stock opened at $5.64 on Wednesday. The company has a 50 day moving average of $6.07 and a two-hundred day moving average of $6.71. The company has a market cap of $41.15 million, a price-to-earnings ratio of -0.43 and a beta of 0.49. Kezar Life Sciences has a 12-month low of $5.20 and a 12-month high of $9.53. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on KZR shares. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th. Wells Fargo & Company dropped their price target on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 19th. Finally, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.